Purpose: Early gastric cancer cases that are estimated to meet indications for treatment before endoscopic submucosal resection are often revealed to be out-of-indication after the treatment. We investigated the short-term treatment outcomes in patients with early gastric cancer according to the pretreatment clinical endoscopic submucosal resection indications. Materials and Methods: We retrospectively reviewed the medical records of patients with early gastric cancer that met the pretreatment endoscopic submucosal resection indications, from 2004 to 2011. Curative resection rate and proportion of out-of-indication cases were compared according to the pre-endoscopic submucosal resection indications. Pre-endoscopic submucosal resection factors associated with out-of-indication in the final pathological examination were analyzed. Results: Of 756 cases, 660 had absolute and 96 had expanded pre-endoscopic submucosal resection indications. The curative resection rate was significantly lower in the patients with expanded indications (64.6%) than in those with absolute indications (81.7%; P<0.001). The cases with expanded indications (30.2%) were revealed to be out-of-indication more frequently than the cases with absolute indications (13.8%; P<0.001). Age of >65 years, tumor size of >2 cm, tumor location in the upper-third segment of the stomach, and undifferentiated histological type in pre-endoscopic submucosal resection evaluations were significant risk factors for outof-indication after endoscopic submucosal resection. Conclusions: Non-curative resection due to out-of-indication occurred in approximately one-third of the early gastric cancer cases that clinically met the expanded indications before endoscopic submucosal resection. The possibility of additional surgery should be emphasized for patients with early gastric cancers that clinically meet the expanded indications.
Introduction
Endoscopic submucosal dissection (ESD) is accepted as the primary treatment for early gastric cancer (EGC) lesions that meet the absolute indications for resection and can be considered as an investigational treatment for lesions that meet the expanded indications and have a negligible risk of lymph node metastasis. 1, 2 After ESD for EGC lesions that meet the final pathological curability criteria for ESD indications, long-term outcomes are favorable and comparable between both criteria for absolute and expanded indications. The 5-year overall survival (OS) rate is 92% to 97% for the patients with absolute indications and 93% to 97% for the patients with expanded indication. [3] [4] [5] Furthermore, the OS after endoscopic resection (ER) was comparable with that after surgery in patients with EGC lesions that met the curability criteria for absolute 6 and expanded indications 7 in the final patho- ESD indications are determined based on several factors, including tumor size, histological type, depth of invasion, and the presence of an ulcer. 2 However, the current clinical evaluation before ESD has limitations in accurately estimating these factors. 8 Owing to the inevitable discrepancies between pretreatment estimation and posttreatment pathological findings, the noncurative resection rates for patients who did not meet the pathological curability criteria for ESD indications have been reported to be between 11% and 21%. 3, [9] [10] [11] An additional surgery is needed for these patients because of the risk of lymph node metastasis.
Recent studies showed that survival was compromised in patients who did not undergo additional surgery after noncurative resection. 12, 13 In the present study, we investigated discrepancies between pre-ESD clinical indications and post-ESD pathological findings in patients who underwent ESD for EGC lesions that met either the absolute or expanded indications in pre-ESD evaluations.
Materials and Methods
Study population
In this retrospective study, we reviewed the medical records of 967 consecutive patients who underwent ESD for 1,032 EGC lesions between September 2004 and August 2011 at the National Cancer Center, Korea. Of these EGC lesions, 276 were excluded because of the following: 1) were not adenocarcinomas as determined after a diagnostic endoscopic biopsy (adenoma lesions and atypical gland), 2) were diagnosed at the remnant stomach after subtotal gastrectomy, 3) were out-of-indication per the diagnostic evaluations, or 4) were multiple in same patients.
The baseline demographic characteristics; pre-ESD diagnostic findings, including endoscopy and pathological results; and final pathological evaluation results after ESD were obtained from the prospectively collected database. This study was approved by the Institutional Review Board (IRB) of the National Cancer Center, Korea (NCC2015-0059). Informed consent was waived for all the patients because the IRB assessed this study as low-risk.
Definition of pre-endoscopic submucosal dissection (ESD) indications and pathological curability criteria for post-ESD indications
Based on pre-ESD evaluations and final pathological evaluation results after ESD, ESD indications were divided into the absolute and expanded indications according to the Japanese Gastric Cancer Treatment Guidelines. 2 The pre-ESD depth of tumor invasion was clinically determined by using conventional white light endoscopy (WLE), abdominal computed tomography (CT), and/or endoscopic ultrasonography (EUS).
Pre-ESD absolute indication was defined as a differentiated tumor measuring ≤2 cm that has no ulcer and is confined to the mucosal layer. 2 The pre-ESD expanded indications included the following types of tumors confined to the mucosal layer: 1) a differentiated tumor measuring ＞2 cm without an ulcer, 2) a differentiated tumor measuring ≤3 cm with an ulcer, and 3) an undifferentiated tumor measuring ≤2 cm without an ulcer. 2 The presence of ulcer was defined when a definite visible ulcer was detected on the tumor upon endoscopic examination. 
Pathological evaluation
The ESD procedures, described in a previous study, 14 were performed by 4 experienced gastroenterologists. All the endoscopists were certified specialty board members of the Korean 
Definitions of endoscopic submucosal dissection outcomes
En bloc resection was defined as removal of the tumor in one piece without fragmentation. Complete resection was defined as removal of the tumor using en bloc resection, with negative horizontal and vertical tumor resection margins. 16 Curative resection was achieved when tumors were completely resected and final pathological evaluation results met the curability criteria for absolute or expanded indications of ER. Table 1 ). No significant differences in sex, comorbid disease, tumor type, and tumor location were observed between the two groups.
Short-term outcomes of endoscopic submucosal dissection (ESD) according to pre-ESD indication
The en bloc resection rate in all the included lesions was vs. 81.7%, respectively; P＜0.001; Table 2 ).
Discrepancies between pre-endoscopic submucosal dissection (ESD) and post-ESD criteria
The discrepancies between the pre-ESD indications and post-ESD criteria are shown in Table 3 Values are presented as median (interquartile range), number (%), or mean±standard deviation. ESD = endoscopic submucosal dissection; EGC = early gastric cancer. Values are presented as number (%). ESD = endoscopic submucosal dissection. *Defined when en bloc resection with a negative resection margin was achieved. † Defined when tumors were completely resected and final pathological results were met with absolute or expanded criteria for endoscopic resection. Values are presented as number only or number (%). ESD = endoscopic submucosal dissection; M = mucosa; UL = ulcer. The ESD indication for EGC lesions were based on the negligible risks of lymph node metastasis that were derived from lymph node risk analysis in a large number of cases of surgically resected specimens. 17 Tumor characteristics, including size, histological type, depth of invasion, and presence of ulceration are Values are presented as number (%). ESD = endoscopic submucosal dissection; M = mucosa; UL = ulcer; SM = submucosa; LVI = lymphovascular invasion. *P-value for distribution of post-ESD criteria between the pre-ESD absolute and expanded indications.
major factors to be considered in the estimation of lymph node metastasis risks. 18 Clinical evaluations for determining the aforementioned factors before ESD include conventional WLE for tumor size estimation, ulcer findings, biopsy for tumor histology, and imaging studies (abdominal CT and/or EUS) for predicting depth of tumor invasion. However, current diagnostic modalities have limitations in accurate assessment, such as the underestimation of tumor size via conventional WLE 19 and the limited efficacy of CT and EUS in predicting depth of tumor invasion. 11, 20, 21 Hence, discrepancies between clinical indications of ESD and the final criteria for curative resection seems inevitable.
Previous studies that compared outcomes of ESD according to the post-ESD criteria reported that the en bloc resection rate did not differ between both post-ESD criteria, but complete resection rates were significantly lower in the expanded criteria than in the absolute criteria groups. 3, 9, 10 In the present study, the en bloc and complete resection rates did not differ between both pre-ESD indication groups according to the pre-ESD evaluation results.
As the endoscopists decided to perform ESD only for EGC lesions that met the ER indications in the pre-ESD evaluations, the complete resection rate did not differ between the expandedand absolute indication groups in the present study. However, the curative resection rate was significantly lower in the pre-ESD expanded indication group than in the pre-ESD absolute indication group (64.6% vs. 81.7%, respectively). In addition, a guideline states that ESD for EGC lesions that meet the expanded indica- In the present study, both lymphovascular and submucosal tumor invasions were the most common causes of out-ofindication. Of the components that comprised ER indications, diagnostic evaluations before ESD have limited roles in predicting the depth of tumor invasion and lymphovascular invasion.
In predicting the depth of tumor invasion, the reported accuracy rates of pre-ESD evaluations are low, ranging from 63% to 74%
as determined via conventional endoscopy 11, 27 and from 67% to 72% as determined via EUS. 11, 21, 27, 28 In addition, the presence of lymphovascular invasion is the single, most important risk factor of lymph node metastasis in EGC patients. However, this risk factor cannot be evaluated or predicted with pre-ESD evaluation;
it can only be determined by performing a pathological evaluation of the resected specimen after ESD. These limitations of pre-ESD evaluations are the main reasons for the discrepancies be- Another limitation is that the results of the pre-ESD evaluation to identify lesion characteristics might have slightly differed between endoscopists.
In conclusion, noncurative resection because of out-of-indication occurred in as many as one third of the cases of EGC lesions that clinically met the pre-ESD expanded indications. Therefore, the possibility of additional surgery should be emphasized to patients with these types of EGC lesions before they undergo ESD treatment, and minimally invasive surgery rather than ESD should be considered as the primary treatment for undifferentiated EGCs.
